BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 36988891)

  • 1. ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer.
    Yang L; Wang H; Guo M; He M; Zhang W; Zhan M; Liu Y
    Cell Oncol (Dordr); 2023 Aug; 46(4):1085-1095. PubMed ID: 36988891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ELF3 suppresses gallbladder cancer development through downregulation of the EREG/EGFR/mTOR complex 1 signalling pathway.
    Nakamura T; Nishikawa Y; Shiokawa M; Takeda H; Yokode M; Matsumoto S; Muramoto Y; Ota S; Yoshida H; Okada H; Kuwada T; Marui S; Matsumori T; Maruno T; Uza N; Kodama Y; Hatano E; Seno H
    J Pathol; 2023 Sep; 261(1):28-42. PubMed ID: 37345534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells.
    Yu Y; Wang J; Xia N; Li B; Jiang X
    Oncol Rep; 2015 Apr; 33(4):1683-90. PubMed ID: 25633045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m6A-dependent DAPK3 degradation.
    Bai X; Chen J; Zhang W; Zhou S; Dong L; Huang J; He X
    Cancer Sci; 2023 Nov; 114(11):4299-4313. PubMed ID: 37700438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p/SET/AKT axis.
    Hu YP; Jin YP; Wu XS; Yang Y; Li YS; Li HF; Xiang SS; Song XL; Jiang L; Zhang YJ; Huang W; Chen SL; Liu FT; Chen C; Zhu Q; Chen HZ; Shao R; Liu YB
    Mol Cancer; 2019 Nov; 18(1):167. PubMed ID: 31752906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential biomarkers for sensitivity of gallbladder cancer cells to gemcitabine.
    Yang C; Xu M; Shen HJ; Zhu HY; Li F; He M; Chen T; Wang J; Shi WJ; Ji F
    Int J Clin Exp Pathol; 2014; 7(2):521-8. PubMed ID: 24551272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of ELF3 facilitates cell growth and metastasis through PI3K/Akt and ERK signaling pathways in non-small cell lung cancer.
    Wang H; Yu Z; Huo S; Chen Z; Ou Z; Mai J; Ding S; Zhang J
    Int J Biochem Cell Biol; 2018 Jan; 94():98-106. PubMed ID: 29208568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
    She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
    J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding RNA SSTR5-AS1 facilitates gemcitabine resistance via stabilizing NONO in gallbladder carcinoma.
    Xue Z; Yang B; Xu Q; Zhu X; Qin G
    Biochem Biophys Res Commun; 2020 Feb; 522(4):952-959. PubMed ID: 31810606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of autophagy by chloroquine enhances the antitumor activity of gemcitabine for gallbladder cancer.
    Wang FT; Wang H; Wang QW; Pan MS; Li XP; Sun W; Fan YZ
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):221-232. PubMed ID: 32654071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of PKMYT1 indicates the poor prognosis and enhances proliferation and tumorigenesis in non-small cell lung cancer via activation of Notch signal pathway.
    Sun QS; Luo M; Zhao HM; Sun H
    Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4210-4219. PubMed ID: 31173292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOAT1 in gallbladder cancer: Clinicopathological significance and avasimibe therapeutics.
    Hong Y; Abudukeremu X; She F; Chen Y
    J Biochem Mol Toxicol; 2024 Jun; 38(6):e23733. PubMed ID: 38770938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155-5p to regulate WEE1 expression.
    Yang Y; Zhang G; Li J; Gong R; Wang Y; Qin Y; Ping Q; Hu L
    Pathol Res Pract; 2021 Dec; 228():153676. PubMed ID: 34753061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate.
    Pandey A; Stawiski EW; Durinck S; Gowda H; Goldstein LD; Barbhuiya MA; Schröder MS; Sreenivasamurthy SK; Kim SW; Phalke S; Suryamohan K; Lee K; Chakraborty P; Kode V; Shi X; Chatterjee A; Datta K; Khan AA; Subbannayya T; Wang J; Chaudhuri S; Gupta S; Shrivastav BR; Jaiswal BS; Poojary SS; Bhunia S; Garcia P; Bizama C; Rosa L; Kwon W; Kim H; Han Y; Yadav TD; Ramprasad VL; Chaudhuri A; Modrusan Z; Roa JC; Tiwari PK; Jang JY; Seshagiri S
    Nat Commun; 2020 Aug; 11(1):4225. PubMed ID: 32839463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of microRNA-205-5p exerts suppressive effects on stem cell drug resistance in gallbladder cancer by down-regulating PRKCE.
    Zhang GF; Wu JC; Wang HY; Jiang WD; Qiu L
    Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32869841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy.
    Xu S; Jiang C; Lin R; Wang X; Hu X; Chen W; Chen X; Chen T
    J Exp Clin Cancer Res; 2021 Nov; 40(1):373. PubMed ID: 34823564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HASPIN is involved in the progression of gallbladder carcinoma.
    Zhu D; Gu X; Lin Z; Yu D; Wang J; Li L
    Exp Cell Res; 2020 May; 390(2):111863. PubMed ID: 31987787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liensinine induces gallbladder cancer apoptosis and G2/M arrest by inhibiting ZFX-induced PI3K/AKT pathway.
    Shen Y; Bian R; Li Y; Gao Y; Liu Y; Xu Y; Song X; Zhang Y
    Acta Biochim Biophys Sin (Shanghai); 2019 Jun; 51(6):607-614. PubMed ID: 31074773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ELF3-AS1 contributes to gastric cancer progression by binding to hnRNPK and induces thrombocytosis in peripheral blood.
    Song S; He X; Wang J; Wang R; Wang L; Zhao W; Wang Y; Zhang Y; Yu Z; Miao D; Xue Y
    Cancer Sci; 2021 Nov; 112(11):4553-4569. PubMed ID: 34418240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PKMYT1: A Potential Target for CCNE1 Amplificated Colorectal Tumors.
    Fang Y; Zhang X; Guo Y; Dong Y; Liu W; Hu X; Li X; Gao D
    Cell Biochem Biophys; 2023 Sep; 81(3):569-576. PubMed ID: 37572218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.